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A simple and sensitive high performance liquid chromatography with ﬂuorescence detection (HPLC–FD)
has been developed for simultaneous quantiﬁcation of doxorubicin (DOX) and its dipeptide conjugate
prodrug (PDOX) in mice plasma. The chromatographic separation was carried out on an Amethyst C18–H
column with gradient mobile phase of 0.1% formic acid and 0.1% formic acid in acetonitrile at a ﬂow rate
of 1.0 mL/min. The excitation and emission wavelengths were set at 490 and 550 nm, respectively. The
method was comprehensively validated. The limits of detection were low up to 5.0 ng/mL for DOX and
25.0 ng/mL for PDOX. And the limits of quantiﬁcation were low up to 12.5 ng/mL for DOX and 50 ng/mL
for PDOX, which were lower than those for most of the current methods. The calibration curves showed
good linearity (R240.999) over the concentration ranges. The extraction recoveries ranged from 84.0% to
88.2% for DOX and from 85.4% to 89.2% for PDOX. Satisfactory intra-day and inter-day precisions were
achieved with RSDs less than 9.1%. The results show that the developed HPLC–FD method is accurate,
reliable and will be helpful for preclinical pharmacokinetic study of DOX and PDOX.
& 2016 Xi'an Jiaotong University. Production and hosting by Elsevier B.V. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Doxorubicin (DOX) is one of the most efﬁcacious drugs used in
cancer chemotherapy [1] for the treatment of leukemia and a
broad range of solid tumors [2]. However, its applications suffer
from serious adverse effects such as heart damage [3], bone
marrow toxicity [4], gastrointestinal disorders [5], and stomatitis
[6]. Our collaborator, Dr. Yan Li group, developed a prodrug of DOX
(PDOX) [7]. As cathepsin B can effectively recognize Phe-Lys-Phe-
Lys and covalently link target peptides with DOX, it can improve
the speciﬁcity of drug and reduce adverse effects [7,8]. The
structures of DOX and PDOX are shown in Fig. 1. The peptide linker
served as a substrate for the tumor-associated protease, cathepsin
B, which is overexpressed in several solid tumors [9,10]. Hence,
DOX will be largely released in tumor sites but rarely in normal
tissues.
It is necessary to establish a sensitive bioanalytical method for
simultaneously monitoring the parent compound and its active
metabolites in mice plasma [11,12]. High performance liquid
chromatography–mass spectrometry/mass spectrometry (HPLC–on and hosting by Elsevier B.V. Th
University.MS/MS) [13] and HPLC with ultraviolet detection (HPLC–UV) [14]
have been applied to the simultaneous determination of DOX and
its some prodrugs. HPLC–MS/MS is highly sensitive and reliable
[15], but the instrument used is expensive, which limits its
availability [16]. HPLC–UV is easy to access, but its sensitivity
is limited. It is well known that ﬂuorescence detector (FD) is
sensitive and selective. Since DOX and PDOX possess native
ﬂuorescence [17], we aimed to develop a sensitive HPLC–FD
method for the determination of DOX and PDOX in biological
matrices in the present study. The ﬂuorescence properties of the
analytes were investigated and the applications of the proposed
method were evaluated. In the experiment, a single-step protein
precipitation by mixing methanol with blood sample was adopted
to eliminate interference of protein. To improve the accuracy and
precision, daunorubicin was selected as the internal standard (IS)
[18].2. Experimental
2.1. Chemicals and reagents
IS, DOX and PDOX were provided by Dr. Yan Li, Wuhan Uni-
versity Zhongnan Hospital. Methanol and acetonitrile (HPLCis is an open access article under the CC BY-NC-ND license
Fig. 1. The structures of (A) DOX and (B) PDOX.
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Deionized water (18.25 MΩ cm, QYSW-20A, Chongqing Qianyan
Water Treatment Equipment Co., LTD) was used throughout the
experiment. All other reagents were of analytical grade and were
commercially available unless otherwise stated.
2.2. Measurement of ﬂuorescence properties
In order to record ﬂuorescence spectra, Luminescence LS55
spectrometer (PerkinElmer, USA) was used. The ﬂuorescence
spectra of DOX and PDOX in methanol were measured. The stock
solutions of these two compounds were diluted to 0.5 μg/mL with
methanol.2.3. HPLC–FD conditions
The HPLC separation was conducted on an LC-20AD HPLC
system (Shimadzu, Japan) with an RF-10AXL ﬂuorescence detector
(Shimadzu, Japan), and a manual injector matched up with a
20 μL sample loop. The separation was conducted on a Sepax
Technologies Ameththyst C18-H column (4.6 mm250 mm,
5 μm). The mobile phase consisted of 0.1% formic acid (aqueous)
and 0.1% formic acid in acetonitrile (organic solvent). A gradient
elution was used with a 1.0 mL/min ﬂow rate, where initially 5%
organic solvents (acetonitrile contained formic acid) was increased
linearly to 65% over 20 min, and ﬁnally decreased to 5% in
20.1 min, where it was held until the end of the 30 min run. The
ﬂuorescence detector was set for excitation at 490 nm and emis-
sion at 550 nm for detection of DOX and PDOX. All analyses were
performed at 30 °C. The mobile phase was ﬁltered through
0.45 μm nylon ﬁlter membranes (Millipore, Milford, USA) and
degassed in an ultrasonic bath before use.
2.4. Animals
All animals involved in the experiments were BALB/c mice,
weighing around 20 g and aged 6–8 weeks. SGC-7901 cells
(5106/0.2 mL per mouse) were injected intraperitoneally into
nude mice on day 0. The mice were fed with PDOX (28.8 mg/kg)
every seven days. All the mice were executed on day 28, and had
the blood collected by removing eyeball. All the mice were kept
under standard conditions with normal access to water and food.2.5. Standard and quality control samples preparation
Appropriate amount of IS, DOX and PDOX were respectively
dissolved in methanol to prepare a stock solution of 1.0 mg/mL.
Then stock solutions were diluted with methanol to the con-
centration of 50 μg/mL as working standard solutions. All solu-
tions were kept at 4 °C before use.
Plasma calibration standards and quality controls (QCs) were
prepared by adding blank plasma with the appropriate amount of
working standard solutions and 20 μL of working IS solution. Ca-
libration standards of DOX were prepared at eight concentrations
ranging from 12.5 ng/mL to 2000 ng/mL, and calibration standards
of PDOX were prepared at seven concentrations ranging from
50 ng/mL to 4000 ng/mL. Promptly after preparation, all solutions
were transferred into amber colored volumetric ﬂasks and kept at
4 °C. Standards calibration samples and QCs were stored at 20 °C
until analysis.
2.6. Samples pretreatment
As for plasma samples, 20 μL of working IS solution and 800 μL
of methanol were added to 200 μL of plasma samples. After vor-
tex-mix for 2 min, the samples were centrifuged at 10,000 rpm for
15 min. The supernatant was transferred into another tube and
evaporated under a stream of nitrogen at 30 °C. The residue was
reconstituted with 200 μL of mobile phase and centrifuged again.
20 μL of the supernatant was injected into the HPLC–FD system for
analysis.
2.7. Method validation
The method was validated for selectivity, linearity, accuracy
and precision and extraction recovery according to the US Food
and Drug Administration (US FDA) guidelines for the bioanalytical
method.
2.7.1. Speciﬁcity
Speciﬁcity was assessed by analyzing blank matrices, blank
matrices spiked with IS, DOX and PDOX, and plasma.
2.7.2. Linearity of calibration curves and lower limits of quantiﬁca-
tion (LLOQ)
Standard curves were measured by plotting the peak area ratios
(analyte/IS) against the theoretical concentration (x) using a 1/x2
Fig. 3. Typical chromatogram of DOX (1), daunorubicin (2) and PDOX (3).
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that could be detected with a relative error and precision (relative
standard deviation, RSD) no more than 20%.
2.7.3. Accuracy and precision
QC samples at three concentrations were analyzed within one
day for intra-day assessment and ﬁve continuous days for inter-
day assessment. A certain amount of DOX (PDOX) was spiked into
blank plasma to obtain 25 ng/mL, 500 ng/mL, 2000 ng/mL of DOX
(PDOX) solutions (n¼5). The accuracy was determined as the
percentage of deviation (relative error, RE%) between the mea-
sured and true concentrations. The precision was evaluated ac-
cording to the RSD. Intra- and inter-day accuracies and precisions
for QC concentrations of less than or equal to 15% were regarded to
be acceptable.
2.7.4. Recovery
Extraction recovery for DOX and PDOX was determined at the
three levels of QC and calculated as the ratio of analyte peak area
of extracted QC samples to that of extracted blank matrices spiked
with DOX and PDOX standard solution.3. Results and discussion
3.1. Characteristics of ﬂuorescence spectrometry for DOX and PDOX
In order to achieve highly sensitive and simultaneous de-
termination of DOX and PDOX, the ﬂuorescence spectra of these
two compounds in methanol were ﬁrst investigated to estimate
the feasibility of the method. All analytes showed typical excita-
tion and emission spectra, as shown in Fig. 2. The emission curves
of DOX and PDOX show a mirror image of their excitation curves.
The maximum excitation wavelengths were both at 490 nm and
the maximum emission wavelengths were obtained at 550 nm and
600 nm. After some pre-experiments, 550 nm was chosen for de-
tection. All compounds provide sufﬁcient and much better ﬂuor-
escence to be detected and quantiﬁed. As a result, in the study, the
native ﬂuorescence of the analytes could be directly detected
without the need of any ﬂuorescence derivatization.Fig. 2. Fluorescence spectra of (A) PDOX and (B) DOX.3.2. Optimization of HPLC conditions
The present study chose different columns, mobile phases and
ﬂuorescence detection wavelengths to optimize HPLC system.
Acetonitrile and methanol, as the most common mobile phase
solvents, were compared for their performance in separation. It
was found that the ﬂuorescence intensities of the analytes were
higher when using acetonitrile as the mobile phase. When 0.1%
formic acid was added into the water, the peak became much
sharper. As a result, acetonitrile and water (containing 0.1% formic
acid) were selected for the further study. However, the problem is
that the retention time of PDOX is long under isocratic elution. It
was solved by appropriate gradient elution, which can be achieved
by increasing acetonitrile from 5% to 65% linearly within 20 min.
After ﬁnishing the run, the gradient was set back to 5% acetonitrile
and the system was allowed to equilibrate. The typical chroma-
togram is shown in Fig. 3.3.3. Method validation
3.3.1. Linearity and LLOQ
The calibration curves, correlation coefﬁcients and linear
ranges of DOX and PDOX are listed in Table 1. The calibration
curves were linear over the concentration ranges of 12.5–
2000 ng/mL for DOX and 50–4000 ng/mL for PDOX with correla-
tion coefﬁcients higher than 0.999. The LLOQ was 12.5 ng/mL for
DOX and 50 ng/mL for PDOX.
3.3.2. Accuracy and precision
Intra- and inter-day precisions and accuracies for DOX and
PDOX are exhibited in Table 2. All results for the samples tested
ranged from 1.9% to 9.1% within the acceptable criteria of 15%,
which suggested that the method was accurate and reproducible
for the determination of DOX and PDOX in mice plasma.Table 1
Standard curves, linear ranges, correlation coefﬁcients, lower limit of detection and
lower limit of quantiﬁcation of DOX and PDOX in plasma samples.
Analyte Regression equation Linear range
(ng/mL)
R2 LLOD
(ng/mL)
LLOQ
(ng/mL)
DOX y¼1.1565xþ0.0015 12.5–2000 0.9992 5.0 12.5
PDOX y¼0.3995xþ0.0007 50.0–4000 0.9999 25.0 50.0
Table 2
Accuracy and precision of DOX and PDOX in mice plasma (n¼5).
Analyte Spiked conc. (ng/mL) Precision (RSD%) Accuracy (RE%)
Intra-day Inter-day Intra-day Inter-day
DOX 25 6.2 7.5 5.6 8.5
500 3.4 4.0 3.1 5.6
2000 2.8 6.8 2.8 4.7
PDOX 50 7.4 9.1 2.1 7.4
500 3.6 5.0 1.9 2.3
2000 2.1 4.5 2.5 4.4
Fig. 4. (A) Chromatograms of the analytes in blank plasma; (B) chromatograms of
blank plasma spiked with DOX, IS and PDOX; (C) chromatograms of plasma sample
obtained after mice were fed with PDOX. Peak identiﬁcation: DOX (1), IS (2) and
PDOX (3).
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The extraction recoveries ranged from 84.0% to 88.2% for DOX
and from 85.4% to 89.2% for PDOX, which demonstrated that re-
coveries were consistent, precise and reproducible at different
concentrations.3.4. Application in mice plasma
It is necessary to analyze drugs in biological samples in phar-
macological and clinical studies. The proposed HPLC–FD method
can be further applied to analyze biological samples with high
sensitivity. The mice plasma samples were injected into the HPLC
system for HPLC–FD analysis. The typical chromatograms of blank
plasma sample, the blank matrices spiked with IS, DOX and PDOX,
and the plasma sample after oral administration of PDOX which
can convert into DOX in vivo are shown in Fig. 4. The retention
time was 15.3 min for DOX, 16.6 min for IS and 17.5 min for PDOX.
Due to the high selectivity, no signiﬁcant endogenous components
can interfere with the analytes and IS which can be well detected
and quantiﬁed in the plasma samples.4. Conclusion
A simple and rapid HPLC–FD method for simultaneous determi-
nation of DOX and PDOX presented in plasma has been developed and
validated. The method has a good linearity, precision, accuracy and
recovery, and can be used for quantitative analysis of DOX and PDOX
at the same time. The proposed HPLC–FD method has further been
successfully applied to the analysis of rat plasma sample after oral
administration of PDOX. The method is rapid, accurate and fully vali-
dated, and can be instructive for content determination in real
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